The Robert Newman Studies on Oleander, Anvirzel and Cardiac Glycosides

[Guest guest]

I think you will find what you are looking for in the file I just

added here to the site:

 

Newman_Studies.doc

 

Click on Files in the yellow navigation bar to the left and you will

find it there amongst a few other nuggest of information.

 

 

oleander soup , <toreadpeoplehealthinfo wrote:

>

> Thank you, Tony, for forwarding this message.

> Very helpful.

> Crandell mentioned a published peer-reviewed article by Dr.Newman and

> others of cardiac glycosides and the science relative to their use in

> tumor therapy.

> Would you please ask him where to find a copy of this article online?

> Thank you very much!

> Angel

>

>

> A message from the CEO of oleander medicine maker Phoenix Biotech

> Posted by: " Tony "

> Thu Apr 10, 2008 12:44 pm (PDT)

> In response to one of our members pleas for further proof a message

> was forwarded to Crandell Addington, CEOt of Phoenix Biotech. Here is

> his reply:

>

> Good morning, all:

>

> We have an agent in Phase I Clinical Trials at M.D.Anderson Phase I

> Clinic currently. You can look it up on www.clinicaltrials.gov by

> using PBI-05204 as the agent. " PBI " identifying Phoenix Biotechnology,

> Inc. You can see the details there. It is administered in capsular

> form, not as a " pill " such as you might associate with the common form

> of aspirin.

>

> This agent is a supercritical extract of Nerium Oleander for which we

> have received a Notice of Allowance from the USPTO. The principal

> cardiac glycoside of this extract is oleandrin, although it does

> contain other molecules that suggest in vitro that they are

> synergistic with the oleandrin.

>

> The year 2000 Phase I Clinical Trial of Anvirzel (published) does note

> three patients with disease stabilization. This Trial was suspended

> when the bolus became to voluminous for the intramuscular route of

> administration to continue. As I recall, it did not approach its

> protocol for MTD (maximum tolerated dose without serious adverse

> advents) that is the primary endpoint of all Phase I Clinical Trials.

> (Joe Nester of Nerium Biotechnology can give you more details.) So,

> the disease stabilization suggests that increased dose levels might

> have had an even more therapeutic result.

>

> I have a friend who was diagnosed with terminal gastronoma almost six

> years ago. He used Anivrzel as adjuvant therapy while receiving the

> conventional " cocktail " at the pancreatic clinic at M.D.Anderson

> Cancer Center. He continues to self-administer Anvirzel to this day,

> and has not received any conventional chemotherapy in years. He

> doesn't mind talking about it. Let me know if you want to talk with him.

>

> There is a recent published peer-reviewed article by Dr.Newman and

> others of cardiac glycosides and the science relative to their use in

> tumor therapy.

>

> Hope this helps.

>

> Have a nice day.

> Crandell Addington

> CEO Phoenix Biotechnology, Inc.

>